<DOC>
	<DOCNO>NCT01380808</DOCNO>
	<brief_summary>The progression free survival could prolong add pseudomonas aeruginosa monotherapy capecitabine .</brief_summary>
	<brief_title>Capecitabine Pseudomonas Aeruginosa Combination Metastatic Breast Cancer ( MBC )</brief_title>
	<detailed_description>efficacy combination much well monotherapy</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Pseudomonas Infections</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<criteria>1 . Female 18 70 year old 2 . Patients histologic prove metastatic breast cancer , unsuitable treat locally . 3 . Patients Her2 negative breast cancer ( HER2 negative one plus IHC test , HER2 two plus IHC , FISH result negative ) 4 . Disease progression anthracycline and/or taxane regimen therapy candidate capecitabine monotherapy 5 . Patients previously treat capecitabine contain regimen response chemotherapy contain capecitabine progress least 4 month last capecitabine treatment 6 . Karnofsky score 70；ECOG 0~2； 7 . Normal function heart , liver , renal bone marrow 8 . WBC≥4×109/L；Hb≥90 g/L；plt≥100×109/L 9 . Got ICF enrollment 1 . Pregnant breastfeed woman positive serum pregnancy test 2 . Uncontrolled brain metastasis . Patients brain metastasis must locally treated disease must stable least one month time enrol 3 . Participation investigational drug study within 4 week precede treatment start . 4 . Concurrent malignancy sit previous cancer within last 5 year , exception adequately treat situ carcinoma cervix uteri basal squamous cell carcinoma skin contralateral breast cancer . 5 . Serious uncontrolled intercurrent infection 6 . Poor compliance</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>July 2013</verification_date>
</DOC>